(Q28259862)

English

The future of immune checkpoint therapy

scientific article

In more languages

edit

Statements

0 references

1 reference

Europe PubMed Central

title

The future of immune checkpoint therapy (English)

0 references

2

James P Allison

0 references

author name string

Padmanee Sharma

series ordinal

1

0 references

language of work or name

English

0 references

publication date

3 April 2015

0 references

published in

Science

0 references

volume

348

0 references

issue

6230

0 references

page(s)

56-61

0 references

cites work

Mutations of the BRAF gene in human cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

The B7 family revisited

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Cancer immunotherapy: moving beyond current vaccines

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

CTLA-4 can function as a negative regulator of T cell activation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

The blockade of immune checkpoints in cancer immunotherapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

LAG-3, a novel lymphocyte activation gene closely related to CD4

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126/SCIENCE.AAA8172

retrieved

21 April 2017

Distinct sets of genetic alterations in melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA8172

retrieved

21 April 2017

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA8172

retrieved

21 April 2017

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1126%2FSCIENCE.AAA8172

retrieved

21 April 2017

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

The TIM gene family: emerging roles in immunity and disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

VISTA Regulates the Development of Protective Antitumor Immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Neoantigens in cancer immunotherapy.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Current clinical trials testing combinations of immunotherapy and radiation.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Targeting CD137 enhances the efficacy of cetuximab.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

LAG-3 in Cancer Immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Signatures of mutational processes in human cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.AAA8172

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

(Q28259862)

The future of immune checkpoint therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)